Repositioning Candidate Details

Candidate ID: R0326
Source ID: DB00886
Source Type: investigational
Compound Type: small molecule
Compound Name: Omapatrilat
Synonyms: Omapatrilat; Omapatrilate
Molecular Formula: C19H24N2O4S2
SMILES: [H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)CC1=CC=CC=C1)C(O)=O
Structure:
DrugBank Description: Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). The inhibition of NEP elevates natriuretic peptide levels, increasing excretion of sodium in urine, dilating blood vessels, and reducing preload and ventricular remodeling. This drug from BMS was not approved by the FDA due to angioedema safety concerns.
CAS Number: 167305-00-2
Molecular Weight: 408.53
DrugBank Indication: For the treatment of hypertension.
DrugBank Pharmacology: Omapatrilat is used to treat hypertension. Vasopeptidase inhibitor that simultaneously inhibits angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). Omapatrilat lowers blood pressure by inhibiting the action of the angiotensin converting enzyme (ACE), which causes blood vessels to constrict. But unlike other drugs, omapatrilat also inhibits another enzyme known as neutral endopeptidase (NEP), which helps blood vessels relax. Omapatrilat demonstrated greater reduction in blood pressure than the ACE inhibitor lisinopril in individuals with salt-sensitive hypertension who typically do not respond well to ACE inhibitors.
DrugBank MoA: Omapatrilat binds to both angiotensin converting enzyme and neutral endopeptidase. This results in a decrease renin-angiotensin-aldosterone production and increase natriuretic peptidase circulation.
Targets: Angiotensin-converting enzyme; Neprilysin
Inclusion Criteria: Indication associated